Effect of antihypertensive treatment on qualitative estimates of microalbuminuria

Journal of Human Hypertension

Volumn 10, Issue 8, 1996, Pages 551-555

  Agrawal, B ^a   Wolf, K ^a   Berger, A ^a   Luft, F C ^b,c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HUMBOLDT UNIVERSITY   (Germany)

^c FRANZ VOLHARD CLINIC   (Germany)

Author keywords

Angiotensin converting enzyme inhibitors; Beta blockers; Cardiovascular risk; Carvedilol; Elderly; Microalbuminuria; Proteinuria

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GERMANY; HUMAN; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIPLE REGRESSION; SCREENING;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 0029969823     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ljungman S. Microalbuminuria in essential hypertension. Am J Hypertens 1990; 3: 956-960.
2. Rambausek M, Fliser D, Ritz E. Albuminuria of hypertensive patients. Clin Nephrol 1992; 38 (Suppl 1): S40-S45.
3. Ritz E, Fliser D. Clinical relevance of albuminuria in hypertensive patients. Clin Investig 1992; 70 (Suppl 1): 5114-5119.
4. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Lancet 1988; ii: 531-534.
5. Agrawal B, Berger A, Wolf K, Luft FC. Microalbumin screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14: 223-228.
6. Marshall SM, Shearing PA, Alberti KGMM. Micral-Test strips evaluated for screening for albuminuria. Clin Chem 1992; 38: 588-591.
7. Biampietro O et al. Which method for quantifying 'microalbuminuria' in diabetics?: comparison of several immunological methods for measurement of albumin in urine. Acta Diabetol 1992; 28: 239-245.
8. Tiu SC, Lee SS, Cheng MW. Comparison of six commercial techniques in the measurement of microalbuminuria in diabetic patients. Diabetes Care 1993; 16; 616-620.
9. Yue TL et al. Carvedilol, a new vasodilator and β-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263: 92-98.
10. Hörner D, Fliser D, Klimm HP, Ritz E. Albuminuria in normotensive and hypertensive individuals attending offices of general practitioners. J Hypertens 1996; 14: 655-660.
11. Marre M et al. Microalbuminuria in uncomplicated hypertension and its reduction by antihypertensive treatment. Diab Metabol 1988; 14: 232-234.
12. Erley CM et al. Microalbuminuria in essential hypertension: reduction by different antihypertensive drugs. Hypertension 1993; 21: 810-815.
13. Bianchi S et al. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994; 7: 23-29.
14. Bigazzi R et al. Long-term effects of a converting enzyme inhibitor and a calcium channel blocker on urinary albumin excretion in patients with essential hypertension. Am J Hypertens 1993; 6: 108-113.
15. Persson B et al. Calcium antagonism in essential hypertension: effect on renal hemodynamics and microalbuminuria. J Int Med 1992; 231: 247-252.
16. Laville M et al. Effect of beta-blockade on albumin excretion rate in essential hypertension. Nephron 1990; 54: 183-184.
17. Ljungmann S et al. Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension. Am J Hypertens 1993; 6: 554-563.
18. Yue TL et al. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 1993; 22: 922-928.
19. Ohlstein EH et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993; 90: 6189-6193.
20. Nagakawa Y, Akedo Y, Kaku S, Orimo H. Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorrheologic variables in hypertension. Eur J Clin Pharmacol 1990; 38 (Suppl 2): S115-S119.
21. Halliwell B. Free radicals, antioxidants, and human disease. Lancet 1994; 344: 721-724.
22. Stehouwer CD et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin dependent diabetes mellitus. Lancet 1992; 340: 319-323.
23. Siegel JE, Krolewski AS, Warram JH, Weinstein MC. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 1992; 3 (Suppl 1): S111-S119.
24. Borch-Johsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin-dependent diabetes mellitus? Br Med J 1993; 306: 1722-1725.